Mostly Markets
Subscribe
Stocks/Health Care/Health Care Technology

Tempus AITEM

Health Care Technology
Solid businessNo profits yet
$72.22−7.22%At the close, 30 Oct 2026
▼ 18.7% over 1 year
Tempus AI over 1 yearDaily close, $, to 30 Oct 2026
$40$60$80Nov2026MarMayJulSep$72.22$40$60$80NovMarJul$72.22
Source: Nasdaq daily closes
Market value–
Price to earnings–
Forward P/E–
Dividend yield–
Year to date+22.3%
One year−18.7%
Next earningsMon 2 Nov, before the open
SectorHealth Care
52-week range (closes)
$41.55$89.85

Quality and valuation

How Tempus AI compares with other health care stocks. A description, not a recommendation.

Tempus AI and 5 health care technology peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: no profits to value

An average business among health care companies, with no profits yet to value.

Tempus AI has no positive earnings to put a price-to-earnings multiple on. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +50.4% vs +7.8%
  • Less profitable (operating margin): −19.8% vs 13.3%
  • Turns less of its sales into cash: −18.4% vs 15.9%

Financials

From Tempus AI's SEC filings, through the quarter ending 30 Jun 2026. Hover or tap a bar for its value.

Revenue grew 21.6% from a year earlierQuarterly revenue, $m, latest Q2 ’26
$0m$100m$200m$300mQ3 ’24Q1 ’25Q3 ’25$382mQ2 ’26$0m$200mQ3 ’24Q1 ’25Q3 ’25$382mQ2 ’26
Source: SEC filings
Growth slowed to +21.6% last quarterRevenue growth, year on year, %
0%25%50%75%Q3 ’24Q1 ’25Q3 ’2521.6%Q2 ’260%50%Q3 ’24Q1 ’25Q3 ’2521.6%Q2 ’26
Source: SEC filings
Operating margin was -19.8% last quarterOperating income as a share of revenue, %
−20%−10%0%Q3 ’24Q1 ’25Q3 ’25−19.8%Q2 ’26−20%−10%0%Q3 ’24Q1 ’25Q3 ’25−19.8%Q2 ’26
Source: SEC filings
Free cash flow was −$263 million over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
−$100m−$50m$0mQ3 ’24Q1 ’25Q3 ’25−$14mQ2 ’26−$100m$0mQ3 ’24Q1 ’25Q3 ’25−$14mQ2 ’26
Source: SEC filings
Last 12 monthsTEMSector median
Revenue growth+50.4%+7.8%
Operating margin−19.8%13.3%
Free cash flow margin−18.4%15.9%

Stories on Tempus AI

We haven't written about Tempus AI yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Health Care Technology, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
ABBVAbbVie$294.89+1.41%+29.1%$521B
MRKMerck$149.52+2.18%+42.0%$369B
UNHUnitedHealth$406.97−0.96%+23.3%$365B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B